MJFF, Seal Rock partnership eyes LRRK2 gene-targeting therapies
Seal Rock has joined an MJFF initiative to develop therapies targeting the LRRK2 gene, which can contribute to Parkinson’s development.| Parkinson's News Today
Seal Rock has joined an MJFF initiative to develop therapies targeting the LRRK2 gene, which can contribute to Parkinson’s development.| Parkinson's News Today
